Despite the lack of information, the ancestry detected in the UK does not appear to interfere with the treatment and vaccine being developed. If another drug that does affect the drug is found, the vaccine platform approved for use in humans (such as mRNA or carrier) will also work. Experts from the coronavirus Sonia Zúñiga explained this.
The team is responsible for monitoring the evolution of the British coronavirus, British COVID-19 Genomics Alliance, Notified on Saturday that the new variant of SARS-CoV-2 requires stronger genome monitoring: the so-called B.1.1.7.
There is a lack of information to confirm that this lineage is more easily spread, more easily spread, more pathogenic, or affects vaccines and treatments that are being developed against covid-19.but Sonia Zuniga,virologist National Biotechnology Center (CNB-CSIC) said that this is still under study and has not yet confirmed the increase in transmission rate.
First, Zúñiga clarified to SINC when referring to B.1.1.7.When we have to talk about Variants Instead of tension. “We talk about stress, In the strict senseWhen the virus has different characteristics, for example, it spreads more, is more pathogenic, or is not neutralized by antibodies. We call all these seemingly mutated mutations until we find that they have different biological properties. “He says.
At the beginning of the battle Vaccination In Spain and Europe, there may be concerns about ignoring new variants of acquired immunity.Although there is still a lack of confirmation information, virologists Don’t believe this new bloodline will affect the vaccine.
This Genome monitoring It has already helped detect other variants of the coronavirus, so in addition to candidate vaccines, it has also found new strategies against them. E.g, D614He said: “This method has been implemented all over the world, and it is well known that this method can neutralize the serum of people infected with the original Chinese strains or animals or vaccinated.”
It doesn’t take a year to wait again
On the other hand, if the mutation that appears does ignore the immunity of the drug being developed, Júñiga clarified that it is not necessary to repeat all the steps of drug development. Clinical Trials Before the vaccine is approved.
“If the platform for vaccines is already available and approved for use in humans, it can be used as messenger RNA [Pfizer/BioNTech y Moderna] o vector [Oxford/AstraZeneca y Janssen], It does not need to go through all stages”, experts said, this will be a process similar to the process. Flu vaccine, And develop once a year.
Yes they will exist Other exams To check its effectiveness, such as production quality control for previous vaccine control or animal testing conducted by pharmaceutical companies, rather than the entire process of standard three-phase clinical trials before the market.